Preliminary results of a first-in-human phase 1b (aCCeleR8-001) study of S-531011, a humanized anti-CCR8 monoclonal antibody, in patients with advanced solid tumors. Efficacy and safety of ozuriftamab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results